You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

List of Excipients in API rifapentine


✉ Email this page to a colleague

« Back to Dashboard


Excipients in NDA-approved (novel) drugs containing rifapentine

Glossary
Company Tradename Ingredient NDC Excipient Potential Generic Entry
sanofi-aventis US LLC PRIFTIN rifapentine 0088-2102 ALUMINUM OXIDE
sanofi-aventis US LLC PRIFTIN rifapentine 0088-2102 CALCIUM STEARATE
sanofi-aventis US LLC PRIFTIN rifapentine 0088-2102 CELLULOSE, MICROCRYSTALLINE
sanofi-aventis US LLC PRIFTIN rifapentine 0088-2102 EDETATE DISODIUM
>Company >Tradename >Ingredient >NDC >Excipient >Potential Generic Entry

Subscribe to access the full database, or Get Started Free

Detailed excipient profiles for rifapentine

Excipient focus: ALUMINUM OXIDE

Excipient focus: CALCIUM STEARATE

Excipient focus: CELLULOSE, MICROCRYSTALLINE

Excipient focus: EDETATE DISODIUM

Excipient focus: FD&C BLUE NO. 2

Excipient focus: FERRIC OXIDE RED

Excipient focus: HYDROXYPROPYL CELLULOSE

Excipient focus: HYPROMELLOSE

Excipient focus: POLYETHYLENE GLYCOL

Excipient focus: PROPYLENE GLYCOL

Excipient focus: SODIUM ASCORBATE

Excipient focus: SODIUM LAURYL SULFATE

Excipient focus: SODIUM STARCH GLYCOLATE TYPE A CORN

Excipient focus: STARCH, CORN

Excipient focus: TITANIUM DIOXIDE

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2025 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
 NCE-1 Patent Challenge Dates 2025 - 2026
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links